NASDAQ Insider Buying: Prospect Capital (NASDAQ:PSEC), CyrusOne (NASDAQ:CONE), National Penn Bancshares (NASDAQ:NPBC), Insys Therapeutics (NASDAQ:INSY), Bank Of The Ozarks (NASDAQ:OZRK)

Prospect Capital Corp. (NASDAQ:PSEC) CEO John F. Barry purchased 100,000 shares of the stock in a transaction dated Friday, June 13th. The stock was purchased at an average cost of $10.37 per share, for a total transaction of $1,037,000.00. Following the completion of the purchase, the chief executive officeronline.wsj.comchief executive officer now directly owns 4,110,959 shares in the company, valued at approximately $42,630,645. Prospect Capital … Continue reading NASDAQ Insider Buying: Prospect Capital (NASDAQ:PSEC), CyrusOne (NASDAQ:CONE), National Penn Bancshares (NASDAQ:NPBC), Insys Therapeutics (NASDAQ:INSY), Bank Of The Ozarks (NASDAQ:OZRK)

Biotech Losers: Insys Therapeutics Inc (NASDAQ:INSY), Enzymotec Ltd (NASDAQ:ENZY), Geron Corporation (NASDAQ:GERN), Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)

Insys Therapeutics, Inc. (NASDAQ:INSY)’s shares have been under pressure recently on news regarding prescribing patterns for Subsys. The stock price of the company tumbled 17.41% and 15.45% in the last two consecutive trading sessions. Insys Therapeutics Inc (NASDAQ:INSY) stock performance was -15.70% in last session and finished the day at $23.01. Traded volume was 3.24million shares in the last session and the average volume of … Continue reading Biotech Losers: Insys Therapeutics Inc (NASDAQ:INSY), Enzymotec Ltd (NASDAQ:ENZY), Geron Corporation (NASDAQ:GERN), Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)

Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX), just announced a positive, top-line result in a Phase 2 clinical trial of their experimental therapy LX4211 in type 1 diabetes. LX4211, an oral, first-in-class, dual inhibitor of sodium glucose transporters 1 and 2, was designed to lower blood glucose levels through two insulin-independent mechanisms of action. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) stock performance was 5.16% in last session and finished the … Continue reading Biotech Volatile Stocks: Lexicon Pharmaceuticals (NASDAQ:LXRX), Corcept Therapeutics Incorporated (NASDAQ:CORT), Insys Therapeutics (NASDAQ:INSY), ANI Pharmaceuticals (NASDAQ:ANIP)

Shares of Regulus Therapeutics Inc (NASDAQ:RGLS) were the target of a significant decrease in short interest in January. As of March 14th, there was short interest totaling 1,460,571 shares, a decrease of 20.3% from the February 28th total of 1,832,140 shares, Analyst Ratings Newsreports. Regulus Therapeutics Inc (NASDAQ:RGLS) stock performance was 5.09% in last session and finished the day at $7.64. Traded volume was 161,836.00million … Continue reading Biotech Bullish Stocks: Regulus Therapeutics Inc (NASDAQ:RGLS), Insys Therapeutics (NASDAQ:INSY), Repligen Corporation (NASDAQ:RGEN), Sarepta Therapeutics (NASDAQ:SRPT)

The Rosen Law Firm, P.A. reminds purchasers of Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR) between March 15, 2012 and January 9, 2014, inclusive (the “Class Period”) of the important Mach 17, 2014 lead plaintiff deadline in the class action seeking remedies under the federal securities laws. Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) stock performance was -5.40% in last session and finished the day at $53.74. Traded volume was 1,222,609 … Continue reading Biotech Losers: Aegerion Pharmaceuticals (NASDAQ:AEGR), Insys Therapeutics (NASDAQ:INSY), NPS Pharmaceuticals (NASDAQ:NPSP), XOMA Corp (NASDAQ:XOMA)

Insys Therapeutics (NASDAQ:INSY) hit a new 52-week high during trading on Tuesday following a better than expected earnings announcement, AnalystRatings.NET reports. Insys Therapeutics Inc (NASDAQ:INSY) stock performance was 21.73% in last session and finished the day at $83.37. Traded volume was 1,203,992 million shares in the last session and the average volume of the stock remained 263.48 million shares. The beta of the stock remained … Continue reading Biotech Gainers: Insys Therapeutics Inc (NASDAQ:INSY), Oxygen Biotherapeutics (NASDAQ:OXBT), Halozyme Therapeutics (NASDAQ:HALO), Cytori Therapeutics (NASDAQ:CYTX)